Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biomark Diagnostics Inc (CSE:BUX)

0.3550 UNCHANGED

Streaming Delayed Price Updated: 9:46 AM EST, Nov 20, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	0.3550
Bid (Size)	0.3550 (1,000)
Ask (Size)	0.3600 (92,000)
Prev. Close	0.3550
Today's Range	0.3550 - 0.3550
52wk Range	0.1800 - 0.3750
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy

November 12, 2025

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX)...

Via Newsfile

BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial

October 07, 2025

Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer...

Via Newsfile

Performance

YTD	+77.5%	+77.5%
1 Month	+6.0%	+6.0%
3 Month	+1.4%	+1.4%
6 Month	+18.3%	+18.3%
1 Year	+73.2%	+73.2%

More News

BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy

September 29, 2025

Via Newsfile

BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership

August 12, 2025

Via Newsfile

BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement

December 29, 2023

Via Newsfile

BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay

December 04, 2023

Via Newsfile

BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term

November 28, 2023

Via Newsfile

BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives

November 14, 2023

Via Newsfile

BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test

November 07, 2023

Via Newsfile

BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium

October 24, 2023

Via Newsfile

BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team

August 30, 2023

Via Newsfile

Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay

August 08, 2023

Via Newsfile

BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting

June 05, 2023

Via Newsfile

BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay

May 31, 2023

Via Newsfile

BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

May 03, 2023

Via Newsfile

BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors

March 16, 2023

Via Newsfile

Biomark Receives Funding Supporting Research and Development Project for Cancer Treatment Monitoring

February 07, 2023

Via Newsfile

BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch

January 11, 2023

Via Newsfile

BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer

November 30, 2021

Via Newsfile

Liquid Biopsy Company BioMark to Present at the 3rd Annual Congress of the International Society of Liquid Biopsy to Be Held October 22, 2021

October 18, 2021

Via Newsfile

Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patients Receiving Immunotherapy

June 29, 2021

Via Newsfile

BioMark Receives $825K Grant to Develop Its Liquid Biopsy Assay for Lung Cancer Screening

June 01, 2021

Via Newsfile

BioMark Announces Change of Auditor

May 31, 2021

Via Newsfile

Biomark to Open a Diagnostic Laboratory in Quebec

April 29, 2021

Via Newsfile

BioMark Announces Exercise of Warrants and Gain DTC Eligibility for Its Common Shares

April 21, 2021

Via Newsfile

Frequently Asked Questions

Is Biomark Diagnostics Inc publicly traded?

Yes, Biomark Diagnostics Inc is publicly traded.

What exchange does Biomark Diagnostics Inc trade on?

Biomark Diagnostics Inc trades on the Canadian Securities Exchange

What is the ticker symbol for Biomark Diagnostics Inc?

The ticker symbol for Biomark Diagnostics Inc is BUX on the Canadian Securities Exchange

What is the current price of Biomark Diagnostics Inc?

The current price of Biomark Diagnostics Inc is 0.3550

When was Biomark Diagnostics Inc last traded?

The last trade of Biomark Diagnostics Inc was at 11/20/25 09:46 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.